Your bank looked at your balance sheet, saw no building and no machines, and said no. Meanwhile the patents sitting in your portfolio are worth more than that bank's branch. In 2026, a growing list of lenders that accept patents as collateral will fund you on exactly those assets. The catch: most founders do not know these lenders exist, and the few who do walk in unprepared and get a polite rejection.
Here is the direct answer. Lenders that accept patents as collateral include specialty venture-debt funds, IP-backed financing programs wrapped by insurers, and royalty-based financiers. Names actively underwriting on intellectual property in 2026 include Western Technology Investment and Horizon Technology Finance, alongside structured IP-backed programs run through large brokers such as Aon. They lend against the value of your IP, not last quarter's revenue. They only say yes when your portfolio is documented, independently valued, and defensible.
Why lenders that accept patents as collateral exist now
Because company value stopped living in factories. Intangible assets now make up more than 90% of the market value of the S&P 500, up from roughly 17% in 1975 (Ocean Tomo). When the asset base of the economy moves from machines to patents, code, and data, lending either follows the value or it slowly dies. The smartest lenders followed.
It also pays off in risk. One widely cited study found startups holding patents default on debt at roughly 6%, versus about 16% for those without. A patent is not only a legal right. To a lender, it is a measurable signal that the borrower is harder to copy and more likely to still be here in three years. That is why patent-backed loans are quietly becoming a standard line item in venture debt, not an exotic one. For the full picture on default math, see our breakdown of how patents lower loan default risk and how patents increase company valuation.
The four types of lenders that accept patents as collateral
There are four categories, and they price very differently. Match the lender to your stage before you pitch, or you waste the meeting.
1. Venture-debt funds
This is where most founders land. Funds such as Western Technology Investment and Horizon Technology Finance fold IP valuation directly into their underwriting. Several now ask for the patent schedule before they ask for the financial model. They typically pair the loan with warrants, so it is not free, but it is non-dilutive principal sized against assets a bank ignores. Best fit: Series A through C companies with a granted portfolio and real customers.
2. IP-backed, insurance-wrapped programs
Brokers and insurers, including programs structured through Aon, will insure the value of a patent portfolio so a lender can advance against it with far less downside. The insurance wrap is what turns a nervous lender into a willing one. Best fit: companies with a high-value, well-documented portfolio that wants larger loan amounts at better rates.
3. Royalty and revenue-based financiers
If your patents already produce licensing income, royalty financiers will advance capital against that future stream. You are borrowing against contracts, not the claims alone. Best fit: founders with at least one signed licensing deal. If that describes you, study the patent licensing revenue model before you sign anything.
4. Specialty IP-collateral lenders
A small set of boutique lenders exists purely to lend against intellectual property. They move faster and understand IP better than any bank, but they price for that expertise. Best fit: situations a generalist lender cannot underwrite, including pre-revenue companies with an exceptional portfolio.
What makes your patents bankable
A patent count is not collateral. A bankable portfolio is. Before any lender that accepts patents as collateral will write a term sheet, four things have to be true.
First, clean ownership. Every assignment recorded, no inventor disputes, no co-ownership surprises. Second, an independent valuation a third party will stand behind, not a number your patent attorney guessed. Third, defensibility: claims that actually block competitors, which is a different question from whether the patent was granted. Fourth, freedom to operate, so the lender knows your own product does not infringe someone else's patent. Miss any one of these and the deal stalls. For the qualification mechanics and typical terms, read our companion guide on IP-backed financing and using patents as collateral, then pressure-test your numbers against how investors actually value your IP.
The mistake that gets founders rejected
Founders walk into these meetings with a patent count and walk out with nothing. The lender does not care that you have eleven patents. The lender cares what those eleven patents are worth, who would pay to license them, and how hard they are to design around. That is a valuation narrative, not a filing list, and almost no founder builds it before the meeting.
This is the work Beyond Elevation does. We have turned many patents into billions in IP value, and we build the documented, defensible valuation story that turns a lender's maybe into a yes. Companies that arrive with that story in hand have raised early-stage capital at up to 10.2x the terms of companies that treated their IP as a legal cost instead of a financeable asset. Beyond Elevation carries a 4.5 Trustpilot rating from founders who stopped leaving that value on the table.
FAQ
Can a pre-revenue startup get a loan against its patents?
Yes, but the options narrow to specialty IP-collateral lenders and insurance-wrapped programs, and the terms are conservative. Expect lower advance rates and higher interest because the lender is pricing the absence of revenue. A strong, independently valued portfolio is what makes a pre-revenue deal possible at all.
Which lenders actually accept patents as collateral in 2026?
Active names include venture-debt funds such as Western Technology Investment and Horizon Technology Finance, plus IP-backed programs structured through brokers like Aon. Beyond those, a layer of boutique IP-collateral lenders and royalty financiers will lend against valued portfolios and existing licensing income.
How much can I borrow against a patent portfolio?
It depends entirely on the independent valuation and the deal structure, not the number of patents. Loan amounts track the defensible value of the IP and any licensing income attached to it. A documented valuation and clean ownership push the advance rate up. Gaps in either push it down.
Is patent-backed lending dilutive?
The principal is debt, so it does not sell equity. Venture-debt deals often attach warrants, which carry a small dilution component, while pure IP-collateral and royalty financing can be fully non-dilutive. It is almost always cheaper on the cap table than raising the same amount of equity.
What is the single biggest reason these loans get rejected?
Undocumented value. Founders bring a list of filings instead of a defensible valuation narrative, and the lender cannot underwrite a number nobody will stand behind. Fixing that one gap, before the meeting, changes more outcomes than anything else.
Your patents are financeable. The question is whether you can prove it to the people writing the checks. Talk to Beyond Elevation and we will build the valuation and the lender-ready story that turns your portfolio into capital.